High visfatin expression in breast cancer tissue is associated with poor survival

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 9, 2011, Pages 1892-1901

  Lee, Yi Chen ^a,b   Yang, Yi Hsin ^c   Su, Jinu Huang ^c   Chang, Hsueh Ling ^d   Hou, Ming Feng ^c,e   Yuan, Shyng Shiou F ^d,f  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d E DA HOSPITAL   (Taiwan)

^e NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^f I SHOU UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; TAIWAN;

BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS;

EID: 80052524202     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0399     Document Type: Article

References (40)

1. Hou W.K., Xu Y.X., Yu T., Zhang L., Zhang W.W., Fu C.L., et al. Adipocytokines and breast cancer risk. Chin Med J (Engl) 2007;120:1592-1596 (Pubitemid 47595751)
2. Brown A., Raynor P., Lee M. Young mothers who choose to breast feed: The importance of being part of a supportive breast-feeding community. Midwifery 2011;27:53-59
3. Begum P., Richardson C.E., Carmichael A.R. Obesity in post menopausal women with a family history of breast cancer: Prevalence and risk awareness. Int Semin Surg Oncol 2009;6:1.
4. Mantzoros C., Petridou E., Dessypris N., Chavelas C., Dalamaga M., Alexe D.M., et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004;89:1102-1107 (Pubitemid 38368397)
5. Chen D.C., Chung Y.F., Yeh Y.T., Chaung H.C., Kuo F.C., Fu O.Y., et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 2006;237:109-114
6. Kusminski C.M., McTernan P.G., Kumar S. Role of resistin in obesity, insulin resistance and Type II diabetes. Clin Sci (Lond) 2005;109:243-256 (Pubitemid 41337128)
7. Wellen K.E., Hotamisligil G.S. Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111-1119 (Pubitemid 40629025)
8. Calle E.E., Kaaks R. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-591 (Pubitemid 39025053)
9. Tilg H., Moschen A.R. Role of adiponectin and PBEF/visfatin as regulators of inflammation: Involvement in obesity-associated diseases. Clin Sci (Lond) 2008;114:275-288 (Pubitemid 351294003)
10. Bae S.K., Kim S.R., Kim J.G., Kim J.Y., Koo T.H., Jang H.O., et al. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett . 2006;580:4105-4113 (Pubitemid 44037574)
11. Gen R., Akbay E., Muslu N., Sezer K., Cayan F. Plasma visfatin level in lean women with PCOS: Relation to proinflammatory markers and insulin resistance. Gynecol Endocrinol 2009;25:241-245
12. Galli M., Van Gool F., Rongvaux A., Andris F., Leo O. The nicotinamide phosphoribosyltransferase: A molecular link between metabolism, inflammation, and cancer. Cancer Res 2010;70:8-11.
13. Bi T.Q., Che X.M. Nampt/PBEF/visfatin and cancer. Cancer Biol Ther 2010;10:119-125
14. Moschen A.R., Kaser A., Enrich B., Mosheimer B., Theurl M., Niederegger H., et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178:1748-1758 (Pubitemid 46154646)
15. Samal B., Sun Y., Stearns G., Xie C., Suggs S., McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994;14:1431-1437
16. Nakajima T.E., Yamada Y., Hamano T., Furuta K., Gotoda T., Katai H., et al. Adipocytokine levels in gastric cancer patients: Resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol 2009;44:685-690
17. Nakajima T.E., Yamada Y., Hamano T., Furuta K., Matsuda T., Fujita S., et al. Adipocytokines as new promising markers of colorectal tumors: Adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci 2010;101:1286-1291
18. Nakajima T.E., Yamada Y., Hamano T., Furuta K., Oda I., Kato H., et al. Adipocytokines and squamous cell carcinoma of the esophagus. J Cancer Res Clin Oncol 2010;136:261-266
19. Patel S.T., Mistry T., Brown J.E., Digby J.E., Adya R., Desai K.M., et al. A novel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis. Peptides 2010;31:51-57
20. Adya R., Tan B.K., Punn A., Chen J., Randeva H.S. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: Novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008;78:356-365 (Pubitemid 351556097)
21. Van der Veer E., Ho C., O'Neil C., Barbosa N., Scott R., Cregan S.P., et al. Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. J Biol Chem 2007;282:10841-10845 (Pubitemid 47100731)
22. Borradaile N.M., Pickering J.G. Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment. Aging Cell 2009;8:100-112
23. Folgueira M.A., Carraro D.M., Brentani H., Patrao D.F., Barbosa E.M., Netto M.M., et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 2005;11:7434-7443 (Pubitemid 41507704)
24. Yonezawa T., Haga S., Kobayashi Y., Takahashi T., Obara Y. Visfatin is present in bovine mammary epithelial cells, lactating mammary gland and milk, and its expression is regulated by cAMP pathway. FEBS Lett 2006;580:6635-6643 (Pubitemid 44827021)
25. Ermilova V.D. [International histological classification of breast cancer by the WHO(1968) and its prognostic value]. Arkh Patol 1980;42:13-19
26. Benson J.R., Weaver D.L., Mittra I., Hayashi M. The TNM staging system and breast cancer. Lancet Oncol 2003;4:56-60.
27. Frierson H.F. Jr, Wolber R.A., Berean K.W., Franquemont D.W., Gaffey M.J., Boyd J.C., et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 1995;103:195-198
28. Yeh Y.T., Ou-Yang F., Chen I.F., Yang S.F., Wang Y.Y., Chuang H.Y., et al. STAT3 ser727 phosphorylation and its association with negative estrogen receptor status in breast infiltrating ductal carcinoma. Int J Cancer 2006;118:2943-2947
29. Hufton S.E., Moerkerk P.T., Brandwijk R., De Bruine A.P., Arends J.W., Hoogenboom H.R. A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett 1999;463:77-82. (Pubitemid 30001722)
30. MacLaren R., Cui W., Cianflone K. Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes. Diabetes Obes Metab 2007;9:490-497 (Pubitemid 47018512)
31. Li Y., Zhang Y., Dorweiler B., Cui D., Wang T., Woo C.W., et al. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J Biol Chem 2008;283:34833-34843
32. Nowell M.A., Richards P.J., Fielding C.A., Ognjanovic S., Topley N., Williams A.S., et al. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: Implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2006;54:2084-2095 (Pubitemid 44051064)
33. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., et al. Visfatin: A protein secreted by visceral fat thatmimics the effects of insulin. Science 2005;307:426-430 (Pubitemid 40139988)
34. Yang H.J., Yen M.C., Lin C.C., Lin C.M., Chen Y.L., Weng T.Y., et al. A combination of the metabolic enzyme inhibitor APO and the immune adjuvant l-1-methyl tryptophan induces additive antitumor activity. Exp Biol Med (Maywood) 2010;235:869-876
35. Nahimana A., Attinger A., Aubry D., Greaney P., Ireson C., Thougaard A.V., et al. The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies. Blood 2009;113:3276-3286
36. Cea M., Zoppoli G., Bruzzone S., Fruscione F., Moran E., Garuti A., et al. APO866 activity in hematologic malignancies: A preclinical in vitro study. Blood 2009;113:6035-6037; author reply 6037-8.
37. Zoppoli G., Cea M., Soncini D., Fruscione F., Rudner J., Moran E., et al. Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. Exp Hematol 2010;38:979-988
38. Van der Veer E., Nong Z., O'Neil C., Urquhart B., Freeman D., Pickering J.G. Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res 2005;97:25-34. (Pubitemid 40982319)
39. Yang H., Lavu S., Sinclair D.A. Nampt/PBEF/Visfatin: A regulator of mammalian health and longevity? Exp Gerontol 2006;41:718-726 (Pubitemid 44223900)
40. Revollo J.R., Korner A., Mills K.F., Satoh A., Wang T., Garten A., et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007;6:363-375 (Pubitemid 350011996)